However, G-CSF levels in individuals with APLAID remained elevated despite the administration of biologics targeting IL-1, for example, arguing that G-CSF is not a nonspecific feature of inflammation in APLAID. This evidence concerns the gene IL1B and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.